Page 67 - Demo

Parkinsonism in GNDs652Figure S2. Patient characteristics and parkinsonian features per genetic disorder0-24$-49P-74u-100%Genetic conditionNumber of casesMale *Intellectual disability *Mean age at motor onsetBradykinesia, hypokinesia or akinesia *Rigidity *Rest tremor *Postural instability *Asymmetric motor symptoms *Progression of motor signs *Reduced DAT binding with dopaminergic Good response antiparkinsonian medication Levodopa-induced dyskinesia *Cognitive decline/ Psychiatric symptomsProposed main cause of parkinsonism: Parkinson’s disease Genetic Drug-inducedCo-existing neurologic disorder: Epilepsy/seizures Dystonia Ataxia OtherMonogenicBeta-propeller protein-associated neurodegeneration (WDR45)43 6/4341/4125 40/41 43/43 8/3412/17 6/6 33/33 4/4 25/327/1362 36/420 351 40/43 21 3413Cerebrotendinous xanthomatosis (CYP27A)22 8/2214/16 34 20/20 18/20 12/18 10/11 12/13 11/12 8/1011/162/455 13/220 130 14/2211 106Rett syndrome (MECP2) 21 6/216/8 12 21/21 16/16 6/211/2 1/3 4/4 0/1 0/3 0/332 1/21010 8/210800POLG 20 10/20 1/2051 19/19 13/15 13/15 2/2 11/13 6/6 8/8 4/5-13 14/200 140 9/200180SYNJ1 20 10/20 0/1826 20/20 17/19 16/20 13/13 19/19 20/20 3/3 9/17 9/1680 20/206 140 15/207 1103DNAJC6a 19 8/168/1916 19/19 19/19 15/19 19/19 9/11 19/19 5/5 11/176/825 19/195 140 11/197203Tyrosine hydroxylase deficiency (TH) 16 5/105/94 11/11 12/13 10/14 1/10/1 11/13- 16/166/1401 12/160 120 13/160 1031Dravet syndrome (SCN1A) 13 5/1213/13 27 13/13 12/12 2/136/139/112/2 0/2 2/13 0/210---- 13/13 13800Neurofibromatosis type I, Von Recklinghausen (NF1) b11 5/111/2 56 2/2 2/2 2/3 1/2 2/2 2/2 1/1 1/2 2/209 9/11900 1/11100-Phosphoglycerate kinase deficiency (PGK1) 10 10/10 8/1022 10/10 9/109/106/7 8/8 10/10 5/5 3/10 3/503 4/10040 7/104306SPG11 10 1/4 5/1015 4/4 3/4 4/4 3/3 2/4 5/5 3/3 5/8 1/410 7/10070 2/100101Neuronal ceroid lipofuscinosis, juvenile (CLN3)8 8/8 0/8<198/8 8/8 0/8 8/8 0/8 8/8 8/8--00---- 8/88000PTRHD1c7 4/7 6/7 24 6/6 3/7 4/6 6/6 5/5 7/7 1/1 6/6 2/613 7/7070 5/71103RAB39B7 7/7 7/7 38 7/7 5/5 6/6 1/1 3/3 6/6 3/7 6/7 3/614 7/7160 5/70104X-linked parkinsonism with spasticity (ATP6AP2)7 7/7 2/7 18 7/7 1/2 4/7 2/2 1/1----00 7/7070 5/72004Alexander disease (GFAP)5 2/5 1/5 55 5/5 5/5 1/2 0/1 2/2 1/1 1/2 1/1-20 3/5021 4/50031Dopa-responsive dystonia,Parkinsonism (NR4A2) 5 3/4 3/5 41 5/5 5/5 4/5 2/2 5/5 5/5 3/3 4/4 1/211 5/5230 3/51300Fragile X syndrome (FMR1) d5 5/5 1/1 58 5/5 1/1 0/1 1/1- 1/1---55 5/5410 1/5010-SPG15 (ZFYVE26)5 4/5 3/4 11 5/5 4/5 2/5- 5/5 5/5 4/4 3/4 1/220 3/5030 2/50002Christianson syndrome – NHE6 (SLC9A6) e 4 2/4 0/3 44 4/4 3/3 1/2 3/4 3/3 2/2 1/1 1/1-20 4/4040 2/40101Dihydropteridine reductase deficiency (QDPR)4 3/3 2/2 13 2/2 3/3 3/4-- 4/4 0/2 3/3 2/403 2/2020 1/41001DNAJC124 2/4 4/4 27 2/2 1/1 1/4-- 1/4 1/3 4/4 3/302 4/4040 1/40100